Taysha Gene Therapies Announces Major Stock Offering

Taysha Gene Therapies ( (TSHA) ) has issued an announcement.

On May 28, 2025, Taysha Gene Therapies announced an underwriting agreement to sell 46,868,687 shares of common stock and pre-funded warrants for 25,858,586 shares in a public offering, expecting to raise approximately $187.4 million. The offering, managed by Jefferies, BofA Securities, Piper Sandler, and Barclays, aims to fund the company’s operations and capital expenditures into 2028, with the closing expected on May 30, 2025.

The most recent analyst rating on (TSHA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Taysha Gene Therapies stock, see the TSHA Stock Forecast page.

Spark’s Take on TSHA Stock

According to Spark, TipRanks’ AI Analyst, TSHA is a Neutral.

Taysha Gene Therapies’ stock score of 57 reflects the company’s significant financial challenges and negative valuation metrics. However, positive technical momentum, promising clinical progress, and a stable financial position provide some upside potential. The overall outlook is tempered by the need for strategic realignment to address financial weaknesses.

To see Spark’s full report on TSHA stock, click here.

More about Taysha Gene Therapies

Taysha Gene Therapies is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The company’s lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder.

Average Trading Volume: 2,847,743

Technical Sentiment Signal: Buy

Current Market Cap: $559.2M

For detailed information about TSHA stock, go to TipRanks’ Stock Analysis page.